mani vaccin maker target coronaviru earli
moderna data support vaccin earli
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research may
estim apr
price data may
rate updat may
currenc amount express
methodolog valu compani
johnson johnson pfizer astrazeneca
sever vaccin maker race develop
critic need vaccin coronaviru dont
expect vaccin develop impact moat
valuat larg cap drug firm vaccin hold
potenti reopen normal activ global moderna
kick earli data around vaccin race
releas first data phase trial
vaccin may conjunct data
support efficaci vaccin mice first data
encourag vaccin produc sort efficaci
toler profil human would allow fda
approv long addit data continu confirm
profil think strongli support idea
vaccin capabl protect individu
viru although yet see data show
whether efficaci also seen older adult long-
term safeti data continu collect one
two year phase trial continu assum
vaccin vaccin develop
johnson johnson pfizer astrazeneca
avail high-risk popul later year base
phase data ten million dose variou
vaccin manufactur avail end
assum broader approv earli base earli data
phase studi suppli broader vaccin
first half expect chang
fair valu estim vaccin manufactur
howev firm coverag sars-
vaccin candid alreadi state sell
price would not-for-profit level
analysi vaccin
pipelin pleas see may report relax
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
analyst note ep calcul divid net earn share outstand
one world largest pharmaceut firm annual sale
billion also spend lead amount research
develop close billion annual histor sold mani
type healthcar product chemic prescript drug
vaccin account major sale top seller includ pneumococc
cardiovascular treatment eliqui immunolog drug xeljanz sell
product global intern sale repres close
total sale within intern sale emerg market major
contributor repres fifth total compani sale
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
dive deeper data two lowest dose
test microgram dose two-shot seri
sampl first patient show bind
antibodi level least high seen
patient recov
specif even importantli vaccin led
level neutral antibodi expect
effect defend volunt viru
similar higher seen recov patient
among eight patient data said moderna
need continu gather evid long-term safeti
start microgram dose phase
start immin larger phase studi
chosen dose start juli expect
microgram dose comment
partnership lonza begin manufactur
vaccin juli hope reach capac
manufactur billion dose year see initi data
next month vaccin develop like
pfizer/biontech oxford/astrazeneca may get
better idea mani vaccin could avail late
year vaccin appear best option
would expect invest -- public privat --
build partner addit manufactur
capac vaccin otherwis think
multipl vaccin maker could build enough suppli
vaccin world popul first half
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
